XML 78 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Other Consolidated Financial Statement Detail
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Other Consolidated Financial Statement Detail OTHER CONSOLIDATED FINANCIAL STATEMENT DETAIL
Supplemental Cash Flow Information
Supplemental disclosure of cash flow information for the years ended December 31, 2021, 2020 and 2019, is as follows:
 For the Years Ended December 31,
(In millions)202120202019
Cash paid during the year for:
Interest$280.8 $272.7 $244.2 
Income taxes247.9 906.7 1,064.5 
Non-cash Operating, Investing and Financing Activity
In the fourth quarter of 2018 we accrued $300.0 million upon reaching $20.0 billion in total cumulative sales of FUMADERM and TECFIDERA (together, the Fumapharm Products), which was paid in the first quarter of 2019. These amounts, net of tax benefit, were accounted for as increases to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG.
Other Income (Expense), Net
Components of other income (expense), net, are summarized as follows:
 For the Years Ended December 31,
(In millions)202120202019
Interest income$11.0 $42.0 $120.0 
Interest expense(253.6)(222.5)(187.4)
Gain (loss) on investments, net(824.9)685.7 204.7 
Foreign exchange gains (losses), net(22.4)(10.7)(7.0)
Other, net(5.6)2.9 (47.0)
Total other income (expense), net$(1,095.5)$497.4 $83.3 
Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.
The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of December 31, 2021, 2020 and 2019:
 For the Years Ended December 31,
(In millions)202120202019
Net gains (losses) recognized during the period on equity securities$(821.1)$693.9 $200.1 
Less: Net gains (losses) realized during the period and on equity securities10.3 12.1 50.0 
Unrealized gains (losses) recognized during the period on equity securities$(831.4)$681.8 $150.1 
The net unrealized losses recognized during the year ended December 31, 2021, primarily reflect decreases in the aggregate fair value of our investments in Denali, Sage, Sangamo and Ionis common stock of approximately $819.6 million.
Accrued Expense and Other
Accrued expense and other consists of the following:
 As of December 31,
(In millions)20212020
Revenue-related reserves for discounts and allowances$802.1 $1,080.6 
Collaboration expense324.7 389.9 
Employee compensation and benefits345.1 333.8 
Royalties and licensing fees234.7 218.5 
Derivative liabilities10.8 181.5 
Current portion of contingent consideration obligations— 149.6 
Other817.8 791.4 
Total accrued expense and other$2,535.2 $3,145.3 
Other Long-term Liabilities
Other long-term liabilities were $1,320.5 million and $1,329.6 million as of December 31, 2021 and 2020, respectively, and included accrued income taxes totaling $664.5 million and $709.9 million, respectively.